WuXi Bio taps equity market for $795m

Covid_testing_575px_adobe_22June20
By Jonathan Breen
30 Jun 2020

WuXi Biologics (Cayman) bagged HK$6.17bn ($795m) on Monday after boosting the size of a new equity issuance.

The Chinese biopharmaceutical company came to the market looking to raise capital to fund expansion of its global capacity, including constructing US-based manufacturing facilities for Covid-19 treatments.

It appointed Morgan Stanley as placing agent for the deal, tasking it with finding at least six investors for the offer, ...

Already a subscriber?

Continue reading this article

Try full access to GlobalCapital

Free trial